Amicus Therapeutics Non-GAAP EPS of $0.31, revenue of $634M
Source: SeekingAlpha
2026-02-20 16:10:08 ET
More on Amicus Therapeutics
- BioMarin Acquiring Amicus -- Both Great Companies, Only One Worth Buying Now
- BioMarin Pharmaceuticals: Amicus Transforms Business Case Overnight
- Key deals this week: Trump Media & Technology, Howard Hughes, BioMarin Pharmaceutical and more
- BioMarin to acquire rare disease drug developer Amicus for $4.8B
- Seeking Alpha’s Quant Rating on Amicus Therapeutics
Read the full article on Seeking Alpha
For further details see:
Amicus Therapeutics Non-GAAP EPS of $0.31, revenue of $634M
Amicus Therapeutics Inc.
NASDAQ: FOLD
FOLD Trading
0.14% G/L:
$14.355 Last:
2,186,418 Volume:
$14.34 Open:
FOLD Latest News
February 20, 2026 04:01:00 pm
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
FOLD Stock Data
$4,416,657,740
301,745,810
0.4%
110
N/A
Biotechnology & Life Sciences
Healthcare
US
Princeton
